News Center
Share the latest news with you
Dr. Cong Xu
2022-09-14
Dr. Cong Xu, MD, PhD, MBA, has over 10-year experiences in pre/clinical research and medical affairs in oncology. He is Principle of Lilly Asia Ventures. Prior to that, he was former Medical Director at Eli Lilly. Dr. Cong Xu led new drug development from strategy to operation across various tumor types including abemaciclib, a CDK4/6 inhibitor. He led investments such as EdiGene, Allist, Dizal, Mirati, Cullinan, ImmuneOnco etc. Dr. Xu obtained his PhD in Clemson University and MBA degree from The University of British Columbia.
About Us
News Recommendation
Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 沪ICP备2024107649号 互联网药品信息证书编号:(沪)-非经营性-2025-0012 /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement
